FIGURE 2 Meta-analysis of the relative risk to receive red blood cell transfusions for cancer patients receiving erythropoietin or standard care
From the following article:
Cancer-related anemia and recombinant human erythropoietin—an updated overview
Julia Bohlius, Olaf Weingart, Sven Trelle and Andreas Engert
BACK TO ARTICLE
Figure 2. Meta-analysis of the relative risk to receive red blood cell transfusions for cancer patients receiving erythropoietin or standard care
Solid squares represent risk estimates for the single studies. The size of the squares are proportional to the sample size and the number of events. Horizontal lines denote 95% CIs. The diamond shows the CI for the pooled relative risks. Values below 1 indicate a relative risk reduction for red blood cell transfusions favoring the erythropoietin group; a–d denotes different treatment arms. Test for overall effect: z = -9.73 (P <0.001), test for heterogeneity chi-square = 57.76, degrees of freedom = 29 (P = 0.0012). Figure modified with permission from reference 50 © (2005) Oxford University Press.